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Abstract Von Willebrand disease (VWD), the most com-
mon hereditary bleeding disorder, is divided into three
types depending on the quantitative (type 1 and 3) or
qualitative (type 2) abnormality of von Willebrand factor
(VWF). About 70–80% of VWD patients can be treated
with the synthetic product desmopressin, while the others
necessitate factor VIII/VWF concentrates. In addition to the
treatment of bleeding episodes, therapeutic regimens
include short- or long-term prophylaxis. While the literature
data on short-term prophylaxis in VWD are consistent and
clearly show the safety and efficacy of such a therapeutic
approach, little evidence is available regarding long-term
prophylaxis, and although the preliminary results are
encouraging, they need to be validated by large prospective
studies.
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Introduction
VonWillebrand disease (VWD), the most common hereditary
bleeding disorder, results from a quantitative or a qualitative
abnormality of von Willebrand factor (VWF) [1–3].
Inherited VWD has been subdivided into three types: In
types 1 and 3, VWD reflect, respectively, the partial or
virtually complete deficiency of VWF, while in type 2,
VWD reflects a qualitative deficiency of VWF. Qualitative
VWD type 2 is further divided into four variants: 2A, 2B,
2M, and 2N, based on the characteristics of dysfunctional
VWF. Type 1 is the most common form of VWD,
accounting for approximately 80% of all cases, and it is
usually characterized by relatively mild bleeding tendency
that primarily involves mucosal bleeding [4, 5]. Mucocuta-
neous bleeding symptoms are also frequent in patients with
type 2 VWD, which affects approximately 20% of VWD
patients. By contrast, patients with the rare type 3 VWD (1–3%
of all cases) have a more severe disease, complicated also by
hemarthroses and muscle hematomas as observed in severe
hemophilia.
The treatment of VWD is based on the type of the
disease: In fact, while desmopressin (DDAVP) is the
treatment of choice for most patients with type 1 VWD, it
is ineffective in patients with the more severe type 3 and in
most patients with type 2 disease where it is necessary to
use VWF-containing factor VIII (FVIII) products [6].
Moreover, responsive patients treated with repeated
DDAVP infusions given to maintain hemostasis (e.g., after
surgery or invasive procedures) may became unresponsive
(phenomenon know as “tachyphylaxis”). Thus, in approx-
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imately 20–30% of VWD patients, the replacement of
VWF and FVIII with plasma-derived concentrates is the
mainstay of treatment [7, 8].
Patients with VWD may require short- or long-term
prophylaxis treatment. Short-term prophylaxis is usually
performed to prevent excessive bleeding after surgery or
invasive procedures, while long-term prophylaxis may be
needed to control recurrent mucosal and joint bleeding
complicating the more severe forms of VWD. These two
latter therapeutic options will be summarized in this review.
Search strategy
An electronic search on MEDLINE and EMBASE without
temporal limits was performed using different combinations
of the following keywords: “von Willebrand disease,”
“VWD,” “von Willebrand factor,” “VWF,” “short-term
prophylaxis,” “long-term prophylaxis,” “prevention,”
“bleeding,” “hemorrhage,” “gastrointestinal bleeding,”
“plasma-derived concentrates,” “clotting factor concen-
trates,” “desmopressin,” “DDAVP,” “treatment,” “therapy,”
“surgery,” “invasive procedures,” “Haemate/Humate-P,”
“Fanhdi,” and “Alphanate.” In addition, the bibliographic
references of all retrieved studies and reviews were
assessed for additional reports of clinical trials. Unpub-
lished works were identified by searching the abstract
books of the most important congresses on this topic
(International Society of Thrombosis and Haemostasis and
World Federation of Hemophilia).
Short-term prophylaxis in von Willebrand disease
There are several reports in the literature on the use of
DDAVP or FVIII/VWF concentrates as prophylaxis of
hemorrhages during surgery or invasive procedures. How-
ever, because of the onset of tachyphylaxis after repeated
DDAVP infusions, most of the major surgical procedures
are managed with plasma-derived concentrates. FVIII/VWF
concentrates licensed in Italy for the treatment of VWD are
Haemate P (CSL Behring), Alphanate (Grifols), Fanhdi
(Grifols), and Immunate (Baxter).
Federici et al. [9] retrospectively collected data from 63
cases of oral surgery in VWD patients and found that local
therapy with tranexamic acid and fibrin glue with DDAVP,
given subcutaneously at a single dose of 0.3 μg/kg before
surgery, can prevent bleeding complication in the majority
(82%) of patients with VWD. Leissinger et al. [10] found
that high-dose DDAVP intranasal spray was effective in
93% of cases in preventing bleeding in 333 patients with
mild hemophilia A or mild/moderate type 1 VWD (172
patients).
In a single-center 10-year retrospective review con-
ducted in UK, Nitu-Whalley et al. [11] identified 27
patients treated with DDAVP for 35 surgical events and
38 patients who received intermediate-purity FVIII/VWF
concentrates for 68 elective surgical events. DDAVP was
administered in a dose of 0.3 μg/kg intravenously over
30 min. As regard to plasma-derived concentrates, for
major surgery, the median pre- and postoperative doses
were 54 and 43 IU/kg, respectively, and for minor surgery,
the median doses varied between 34 and 52 IU/kg
preoperatively and between 27 and 37 IU/kg postopera-
tively. The effectiveness of hemostasis was excellent in 32
events (91%) treated with DDAVP and in 56 events (82%)
treated with concentrates.
The intermediate-purity FVIII/VWF concentrate Hae-
mate P was utilized in a large retrospective study organized
by the Canadian Hemophilia Centers. Patients were treated
for 437 events, including bleeding episodes and surgical
procedures. The rates of excellent-to-good responses were
97% overall and 99% in surgical procedures. The median
dose of concentrate per infusion used to treat surgical
events was 69.1 IU VWF:RCo/kg (range 11.9–222.8) [12].
We have reported the experience of three Italian
hemophilia centers on 26 VWD patients who underwent
43 surgical or invasive procedures (14 major surgery, 11
minor surgery, 11 dental extractions, and seven invasive
diagnostic procedures) under coverage with Haemate P
[13]. The mean daily dose of the concentrate given was
39.3 IU VWF:RCo/kg (range 25–52.5) for major surgery,
28.7 IU VWF:RCo/kg (range 21.4–34.8) for minor surgery,
24.0 IU VWF:RCo/kg (range 23.5–25) for dental extrac-
tions, and 32.3 IU VWF:RCo/kg (range 27.3–37) for
invasive procedures. The mean days of treatment were 9.7
(range 5–23) for major surgery, 4.2 (range 2–7) for minor
surgery, 1.6 (range 1–5) for dental extractions, and 2.7
(range 1–5) for invasive procedures. As only a bleeding
episode was recorded without drug-related adverse events,
we concluded that Haemate P was safe and effective in
preventing excessive bleeding after major and minor
surgery or invasive procedures in VWD patients.
More recently, an open-label prospective study collected
data from 39 subjects undergoing 42 urgent surgical
treatment events [14]. The median loading dose based
upon VWF:RCo activity was 82.3 IU/kg (range 32.5–
216.8), and the median maintenance dose per infusion was
52.8 IU kg (range 24.2–196.5) for a median of 3 days
(range 1–50 days). The median number of infusions per
event was 6 (range 1–67 infusions). Bernstein et al. [15]
enrolled 35 VWD patients who received Haemate P as
prophylaxis of excessive bleeding during elective surgery
(25 major, seven minor, and three oral surgery) and found
an effective hemostasis in 91.4% of the cases. An Italian
retrospective multicenter cohort study [16] evaluated the
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response to Haemate P in 100 VWD patients treated for
bleeding, surgeries, or prophylaxis and recorded a 97% of
excellent/good clinical response in the 56 patients who
underwent 73 surgical or invasive procedures.
Finally, a prospective multicenter trial on 29 subjects
with VWD undergoing elective surgery found that Haemate
P, whose preoperative loading dose was based on a
pharmacokinetic study, provided an excellent or good
hemostasis in 96.3% of subjects on the day of surgery
and 100% on the following days [17].
The highly purified, doubly virus-inactivated FVIII/
VWF concentrate Fanhdi has been reported to be effica-
cious in the management of VWD in a retrospective
clinical study [18]. In 22 patients, 12 bleeding episodes
and 14 invasive procedures were treated with Fanhdi.
There was 93% excellent or good efficacy and no adverse
events.
The results of a large international prospective study by
the Alphanate study Group were published in 2002 and
included 39 patients receiving prophylactic treatment for 71
surgical or invasive diagnostic procedures. The median
number of infusion per procedure was 3, and the dosages
for the first and subsequent infusions were 60 and 40 IU/kg
VWF:RCo, respectively. A good clinical response with this
FVIII/VWF concentrate was observed in 96% of patients
[19]. In this study, it was also demonstrated that surgery
could be safely undertaken even when Alphanate did not
correct the bleeding time.
Goudemand et al. [20] reported the French clinical
experience on the use of the very-high-purity VHP VWF
concentrate in 75 VWD patients treated on 99 occasions
either to control spontaneous bleeding or to prevent
hemorrhagic risk associated with surgery. Successful
treatment of 31 minor and 23 major surgical procedures
was reported.
As a whole, the literature results (Table 1) document that
20–50 IU/kg of FVIII/VWF concentrates given once daily
until healing is complete are hemostatically effective in
preventing bleeding in more than 90% of surgical or
invasive procedures. Thus, for major procedures, FVIII
and VWF:RCo levels should be raised to 80–100 UI/dl at
the time of surgery and maintained above 50 IU/dl for at
least 7–14 days. For minor procedures, FVIII and VWF:
RCo levels above 50 IU/dl at the time of surgery are
advisable, followed by levels above 30 IU/dl for at least 5–
7 days. Finally, dental extractions or invasive procedures
may be managed with a single concentrate infusion aimed
to reach VWF:RCo/FVIII levels of about 50 IU/dl [21, 22].
However, the accumulation of FVIII that is exogenously
infused together with that endogenously synthesized and
stabilized by the infused VWF may result in very high
FVIII concentrations (>150 IU/dl) when several infusions
are given for severe bleeding episodes or to cover major
surgery. There is some concern that sustained high concen-
trations of FVIII may increase the risk of postoperative
deep-vein thrombosis, as suggested by recent observations
[23]. Therefore we suggest, when repeated injections of
FVIII/VWF concentrates are administered, to monitor daily
FVIII plasma levels. To avoid high postinfusion FVIII
plasma levels, a high-purity VWF concentrate with low
FVIII content (Wilfactin, LFB) has been recently devel-
oped, and its efficacy has been tested in a prospective study
on 50 VWD patients [24]. The hemostatic outcome was
judged excellent or good in all the 108 surgical or invasive
procedures performed, and no adverse thrombotic compli-
cations were recorded.
Long-term prophylaxis in von Willebrand disease
Patients with more severe forms of VWD may have
recurrent episodes of mucocutaneous bleeding and also
hemarthrosis and hematomas and thus are candidate for
long-term secondary prophylaxis [25, 26]. However,
whereas prophylaxis in hemophilia has become widespread
in recent years, this mode of treatment appears to be
practiced only occasionally in VWD patients, and literature
data are scarce [27, 28].
An Italian cohort study [29] on 452 VWD patients
regularly followed up included 11 patients in a long-term
prophylaxis program because of frequent recurrence of
bleeds at the same sites. Prophylaxis was started because of
gastrointestinal bleeds in seven patients (one type 3, two
type 2A, one type 2M, and one type 1) and for joint bleeds
in four type 3 patients. Effectiveness of prophylaxis was
based on resolution/reduction in bleeding as well as on the
number of transfused red blood cells (RBC) and days of
hospitalization. Prophylaxis stopped bleeding in eight
patients and largely reduced hospitalization and RBC
transfusions in the remaining three. When prophylaxis
was compared with previous on-demand regimen in all 11
cases, the annual total FVIII IU of concentrate as well as
the number of RBC used and days of hospitalization were
significantly reduced.
Coppola et al. [30] reported the benefit of a long-term
prophylaxis regimen with Haemate P, given at a dose of
40 IU/kg thrice weekly, in a patient with type 3 VWD and
recurrent severe gastrointestinal bleeding because of mul-
tiple vascular mucosal abnormalities. Similarly, we reported
the efficacy of Haemate P (2,000 IU on alternate days) as
prophylaxis of recurrent bleeding from a malignant esoph-
ageal ulcer [31].
The largest experience regarding secondary long-term
prophylaxis has been collected in Sweden in 37 patients
with severe forms of VWD (three type 1, three type 2, three
type 2B, and 28 type 3) [27]. The median age was 33 years
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with patients starting prophylaxis at the age of 13 years.
Prophylactic treatment was defined as at least one infusion
per week for 45 weeks annually. The main indications for
prophylaxis were joint bleeds or nose/mouth bleeds, and
some patients required prophylaxis for menorrhagia or
gastrointestinal bleeding. The doses used for prophylaxis
ranged from 12 to 50 IU of FVIII/kg (mean 24 IU). The
injection frequency ranged from 1 to 3 times weekly,
depending on the bleeding pattern and response to
treatment. The median duration of prophylaxis was 11 years,
and most patients continued indefinitely. The authors found
that the number of bleeds was reduced dramatically during
prophylaxis. Another important observation of the study
was that children who started prophylaxis because of nose
or mouth bleeds never reported joint bleeds or developed
signs of arthropathy. There were no reports of thrombosis.
The importance of prophylaxis in preventing arthropathy
was recently outlined by Traivaree et al. [32] who shifted
four type 3 VWD children with severe musculoskeletal
bleeds from on-demand treatment to a regular long-term
prophylaxis (55 UI/kg weekly or twice weekly).
Finally, a retrospective survey of data records on VWD
patients organized among ten Italian hemophilia centers
collected 17 cases of long-term secondary prophylaxis with
Haemate P performed to prevent recurrent bleeding at the
same site (47% in the gastrointestinal tract and 35% in
Table 1 Literature results on short-term prophylaxis in von Willebrand disease
Author, year
[reference]





DDAVP 27 20 type 1, 7 type 2 27 oral surgery 0.3 μg/kg IV 100
Leissinger,
2001 [10]
DDAVP 37 37 type 1 37 oral or surgical
procedures
1.5 mg/ml IN 93
Nitu-Whalley,
2001 [11]
DDAVP 35 25 type 1, 2 type Ma 3 major, 13 minor, 19
oral surgeries




Haemate P 73 26 type 1, 20 type 2, 21
type 3, 6 NI





Haemate P 43 19 type 1, 7 type 2b 14 major, 11 minor, 11






Haemate P 42 16 type 1, 9 type 2,
8 type 3, 6 NIc







Haemate P 35 17 type 1, 12 type 2,
13 type 3d







Haemate P 73 19 type 1,
27 type 2,
10 type 3e
17 major, 28 minor, 19






Haemate P 29 10 type 1, 11 type 2, 8
type 3f





Fanhdi 14 5 type 1, 7 type 2,
2 type 3







Alphanate 71 6 type 1, 19 type 2,
14 type 3g














Wilfactin 108 5 type 1, 25 type 2,
14 type 3h
43 major or minor, 14




DDAVP, desmopressin; VWD, von Willebrand disease; VWF, von Willebrand factor; FVIII:C, factor VIII coagulant activity; IV, intravenously; IN,
intra nasal; NI, not indicated; VWF:RCo, von Willebrand factor ristocetin cofactor; IP, invasive procedures; d, day.
a 27 VWD patients underwent 35 surgical procedures.
b 26 VWD patients underwent 43 surgical or invasive procedures.
c 39 VWD patients underwent 42 urgent surgical procedures.
d 35 of the 42 enrolled VWD patients underwent surgical procedures.
e 56 VWD patients underwent 73 surgical or invasive procedures.
f 27 of the 29 enrolled VWD patients underwent surgical procedures.
g 39 VWD patients underwent 71 surgical or invasive procedures.
h 44 VWD patients underwent 108 surgical or invasive procedures.
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joints) [16]. The FVIII/VWF concentrate was given three
times (53% of cases) or twice (47%) a week, with clinical
responses rated as excellent/good in 100% of cases. No
serious adverse events, including thrombosis, were reported.
Conclusions
While the literature data document that short-term prophy-
laxis in von Willebrand disease is safe and effective,
preliminary data on long-term prophylaxis are encouraging,
but large prospective studies must be performed before
detailed recommendations can be made.
In fact, several issues remain to be addressed regarding
the long-term prophylaxis in VWD such as dosing, cost-
effectiveness of this regimen vs on-demand regimen, and
impact on quality of life. To address these issues, an
international study, the von Willebrand Disease Prophylaxis
Network (vWD PN), has been initiated [33].
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